Skip to main contentAI and Advanced
/
GLAND · NSEMarket ticker unavailable · configure an authorised index feed
GL
NSE · Equity shares · Biotechnology & Drugs-96.50 · -3.32%
Gland Pharma GLAND
NSE:INR 2,812.5
BSE:INR 2,617.5
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for GLAND
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 2,909
Day rangeINR 2,792.4 — INR 2,914.2
52-week rangeINR 1,573.6 — INR 3,042
Volume7.49 L
Market cap43,074.14
P/E27.2
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)6,430.65
Net Income (INR Cr)1,027.32
Rev Growth (5 Year %)13.18
EPS Growth (5 Year %)-0.23
P/E Ratio27.2
Book Value604.25
EPS63.33
Price/BV4.65Computed
Research path: Interpret Gland Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
GLANDGland Pharma1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 12,510.85 | 11,224.92 | 10,661.25 |
| Accumulated Depreciation Total | -2,204.01 | -1,424.66 | -1,044.91 |
| Cash Equivalents | 200 | 200 | Not available |
| Other Liabilities Total | 236.89 | 187.38 | 177.7 |
| Accrued Expenses | 184.46 | 146.87 | 38.98 |
| Long Term Debt | 69.93 | 77.66 | 106.54 |
| Common Stock Total | 16.48 | 16.48 | 16.47 |
| Other Equity Total | 468.82 | 37.83 | -17.56 |
| Other Current Assets Total | 0.14 | 0.1 | 100.77 |
| Prepaid Expenses | 40.95 | 39.24 | 38.46 |
| Total Assets | 12,510.85 | 11,224.92 | 10,661.25 |
| Current Portof LT Debt/Capital Leases | 60.55 | 50.51 | 63.83 |
| Additional Paid-In Capital | 1,933.04 | 1,933.04 | 1,929.23 |
| Cash | 353.57 | 2,356.21 | 357.09 |
| Total Equity | 10,357.95 | 9,150.74 | 8,723.84 |
| Retained Earnings(Accumulated Deficit) | 7,939.61 | 7,163.39 | 6,795.7 |
| Total Common Shares Outstanding | 16.48 | 16.48 | 16.47 |
| Property/Plant/Equipment Total-Gross | 6,636.03 | 5,368.55 | 4,875.06 |
| Tangible Book Valueper Share Common Eq | 604.25 | 533.93 | 508.13 |
| Goodwill Net | 293.87 | 248.2 | 242.26 |
| Total Liabilities | 2,152.9 | 2,074.18 | 1,937.4 |
| Total Debt | 283.59 | 313.73 | 372.17 |
| Short Term Investments | 2,805.51 | 396 | 1,581.66 |
| Cashand Short Term Investments | 3,359.08 | 2,952.21 | 1,938.75 |
| Total Receivables Net | 2,341.21 | 2,058.06 | 1,890.83 |
| Notes Payable/Short Term Debt | 129.81 | 156.07 | 167.12 |
| Deferred Income Tax | 214.38 | 214.81 | 220.12 |
| Accounts Receivable-Trade Net | 2,107.7 | 1,748.31 | 1,696.63 |
| Property/Plant/Equipment Total-Net | 4,432.02 | 3,943.89 | 3,830.15 |
| Total Current Liabilities | 1,608.4 | 1,564.85 | 1,398.36 |
| Total Inventory | 1,785.41 | 1,733.33 | 1,676.33 |
| Accounts Payable | 833.87 | 820.41 | 862.69 |
| Other Currentliabilities Total | 399.71 | 390.98 | 265.75 |
| Total Long Term Debt | 93.23 | 107.15 | 141.22 |
| Intangibles Net | 108.62 | 105.7 | 112.22 |
| Other Long Term Assets Total | 98.28 | 85.63 | 107.21 |
| Note Receivable-Long Term | 51.28 | 58.56 | 69.76 |
| Total Current Assets | 7,526.79 | 6,782.94 | 5,645.15 |
| Capital Lease Obligations | 23.3 | 29.49 | 34.68 |
| Long Term Investments | Not available | 0 | 654.5 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio4.3
Price to Sale Ratio6.70
Growth
Debt 5Yr CAGR %124.3
Margins
Operating Margin 12m18.37
Operating Margin 5y Avg20.53
Net Profit Margin 12m15.98
Net Profit Margin 5y17.45
Yield
Dividend Yield %0.79
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk36.98
Analyst consensus
ConsensusBuy
Consensus score2.13
Analyst opinions15
Strong Sell count1
Sell count2
Hold count2
Buy count3
Strong Buy count7
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 51.77%
- FII
- 8.74%
- MF
- 28.23%
- Other
- 11.26%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Customs slaps Rs 7 cr tax, penalty on Gland Pharma - The Times of IndiaMarket news · 22 Jul 2026, 12:04 am
Customs slaps Rs 7 cr tax, penalty on Gland Pharma The Times of India
Gland Pharma reappoints Udo Vetter, appoints William Keller - scanx.tradeMarket news · 21 Jul 2026, 12:30 am
Gland Pharma reappoints Udo Vetter, appoints William Keller scanx.trade
Gland Pharma Slapped with Rs 3.53 Crore IGST Demand, Penalty, Plans to Challenge Order - Medical DialoguesMarket news · 18 Jul 2026, 5:12 pm
Gland Pharma Slapped with Rs 3.53 Crore IGST Demand, Penalty, Plans to Challenge Order Medical Dialogues
Gland Pharma: What Should You Do? - BusinessLineMarket news · 11 Jul 2026, 10:41 pm
Gland Pharma: What Should You Do? BusinessLine
Corporate actions
Events
- annual General MeetingAGM
- dividendRs.20.0000 per share(2000%)Final Dividend
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Gland Pharma
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, New Chemical Entities (NCE)-1s, First-to-File products, and 505(b)(2) filings. The Company manufactures a range of dosage formulations, including solutions, suspensions, and lyophilized products. Its product portfolio includes delivery methods such as pre-filled syringes, vials, ampoules, bags, and dry powder injections. It also produces generic injectables in liquid, lyophilized, suspension, and pre-filled syringe forms. Its molecules include Enoxaparin Sodium, Cisplatin, Lacosamide, Rocuronium Bromide, Zoledronic Acid, Vancomycin, and others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynecological, Hormones, and others. The Company functions primarily on a business-to-business model. Its subsidiary is Gland Pharma International Pte. Ltd.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- GLAND
- BSE Code
- 543245
Questions
Stock FAQ
What is the symbol and ISIN of Gland Pharma?
Gland Pharma has the symbol GLAND and ISIN - INE068V01023.
What is the current price of Gland Pharma?
Gland Pharma is currently trading at INR 2,812.50.
What are the year high and year low of Gland Pharma?
Gland Pharma has a year high of INR 3,042.00 and a year low of INR 1,573.60.
What is the market capitalization of Gland Pharma?
Gland Pharma has a market capitalization of INR 43,074.14 crore.
What is the P/E ratio of Gland Pharma?
Gland Pharma has a P/E ratio of 27.20.
What is the dividend yield of Gland Pharma?
Gland Pharma has a dividend yield of 0.79%.
How is the financial performance of Gland Pharma based on revenue, net income, and EPS?
Gland Pharma has revenue of INR 6,430.65 crore, net income of INR 1,027.32 crore, and EPS of INR 63.31.
What is the book value of Gland Pharma?
Gland Pharma has a book value of INR 604.25.
What is the debt-to-equity ratio of Gland Pharma?
Gland Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Gland Pharma?
Gland Pharma has a price-to-book ratio of 4.65 and a price-to-sales ratio of 6.70.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.